Abstracts tagged "glucocorticoids"

Abstract Number: 2523 • ACR Convergence 2025
Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
Yusuke Ushio¹, Satoshi Omura², Daiki Nakagomi³, Yoshiyuki Abe⁴, Makoto Wada⁵, Naoho Takizawa⁶, Atsushi Nomura⁷, Yuji Kukida⁸, Naoya Kondo⁹, Hirosuke Takagi¹⁰, Koji Endo¹¹, Shintaro Hirata¹², Naoto Azuma¹³, Tohru Takeuchi¹⁴, Shoichi Fukui¹⁵, Kazuro Kamada¹⁶, Ryo Yanai¹⁷, Yusuke Matsuo¹⁸, Yasuhiro Shimojima¹⁹, Ryo Nishioka²⁰, Ryota Okazaki²¹, Tomoaki Takata²², Mayuko Moriyama²³, Ayuko Takatani²⁴, Yoshia Miyawaki²⁵, Tsuyoshi Shirai²⁶, Takafumi Ito²⁷, Isao Matsumoto²⁸, Toshihiko Takada²⁹, Toshiko Ito-Ihara³⁰, Takashi Kida³¹, Nobuyuki Yajima¹⁷, Takashi Kawaguchi³², Yutaka Kawahito³¹ and Hiroaki Dobashi³³, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita District, Kagawa, Japan, ²Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, ⁴⁶⁵, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan, ³Department of Rheumatology, University of Yamanashi Hospital, Chuo-shi, Yamanashi, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University, Bunkyo-Ku, Tokyo, Japan, ⁵Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto-shi, Kyoto, Japan, ⁶Department of Rheumatology, Chubu Rosai Hospital, Nagoya city, Aichi, Japan, ⁷Immuno-Rheumatology Center, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁸Department of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kamigyou, Kyoto, Japan, ⁹Department of Nephrology, Kyoto Katsura Hospital, Nishikyo-ku, Kyoto, Japan, ¹⁰Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Kagoshima, Japan, ¹¹Department of General internal medicine, Tottori Red Cross Hospital, Tottori-city, Tottori, Japan, ¹²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹³Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, ¹-¹ Mukogawa-cho, Nishinomiya-shi, Hyogo, Japan, ¹⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ¹⁷Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Kyosai Hospital, Meguro-ku, Tokyo, Japan, ¹⁹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ²⁰Department of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan, ²¹Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan, ²²Division of Gastroenterology and Nephrology, Tottori University, Yonago, Tottori, Japan, ²³Department of Rheumatology, Shimane University Faculty of Medicine, Izumo-shi, Shimane, Japan, ²⁴Rheumatic Disease Center, Sasebo Chuo Hospital, Sasebo-shi, Nagasaki, Japan, ²⁵Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ²⁶Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ²⁷Division of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Ichiharashi, Chiba, Japan, ²⁸Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan, ²⁹Department of General Medicine, Shirakawa Satellite for Teaching And Research (STAR) Fukushima Medical University, Shirakawa, Fukushima, Japan, ³⁰The Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan, ³¹Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan, ³²Department of Clinical Assessment, Tokyo University of Pharmacy and Life Sciences, Hachioji-city, Tokyo, Japan, ³³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Glucocorticoids (GCs) are a cornerstone of remission induction therapy in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), but long-term GC use is associated…
Abstract Number: 1528 • ACR Convergence 2025
Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus
Esteban C. Garza-Gonzalez¹, Fernanda M. Garcia-Garcia², Oscar Azael Garza-Flores³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú², Jose R Azpiri-Lopez⁵, Iris J. Colunga-Pedraza², Jesus Alberto Cardenas-de la Garza⁶, Dionicio A. Galarza-Delgado² and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
Abstract Number: 0746 • ACR Convergence 2025
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Fatima Hassan¹, Michael Putman² and Sebastian E Sattui³, ¹Medical College of Wisconsin, Menomonee Falls, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Frailty, a syndrome associated with decreased physiologic reserve, is associated with adverse outcomes. The prevalence and impact of baseline frailty on the risk of…
Abstract Number: 0238 • ACR Convergence 2025
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Alessia Gatti¹, Francesca Regola¹, Giulia Fontana², Jacopo Mora², Mario Andrea Piga³, Gianluca Moroncini³, Rossella Acquaviva⁴, Palma Carlucci⁴, Silvia Noviello⁴, Angelo Vacca⁴, Paolo Delvino⁵, Enrico Heffler⁶, Emanuele Nappi⁶, Jakub Moll⁷, Jan Schroeder⁷, Laura Losappio⁷, Federica Davanzo⁸, Roberto Padoan⁹, Paolo Cameli¹⁰, Edoardo Conticini¹¹, Greta Pacini¹², Alvise Berti¹², Lorenzo Vrola¹³, Paola Tomietto¹³, Benedetta Fazzi¹⁴, elena treppo¹⁵, Luca Quartuccio¹⁴, Jan Willem Cohen Tervaert¹⁶, Sabrina Arnold¹⁷, Prof. Dr. med. Peter Lamprecht¹⁸, Florence Roufosse¹⁹, Ilaria Cavazzana¹, Franco Franceschini²⁰, Giacomo Emmi²¹ and Paola Toniati²², ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁴Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, ⁵Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, ⁷Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, ⁸Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁹Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ¹⁰University of Siena, Siena, Italy, ¹¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ¹²Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, ¹³UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, ¹⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, ¹⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, ¹⁸University of Lübeck, Lübeck, Germany, ¹⁹Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, ²⁰University of Brescia, Brescia, Brescia, Italy, ²¹Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, ²²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy
Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
Abstract Number: 2469 • ACR Convergence 2025
Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Heh Shiang Sheu¹, Wen Nan Huang¹, Yao-Fan Fang², Tai-Ju Lee³, Ling-Ying Lu⁴, Ming-Han Chen⁵, Der-Yuan Chen⁶, Fu-Chiang Yeh⁷, Yu-Wan Liao¹, Chang-Youh Tsai⁸, Tsu-Yi Hsieh¹, Song-Chou Hsieh⁹, Shue-Fen Luo², Yu-Jih Su¹⁰, Yeong-Jian Jan Wu¹¹ and Chun chi Lu¹², ¹Taichung Veterans General Hospital, Taichung, Taichung, Taiwan (Republic of China), ²Chang Gung Memorial Hospital, Taoyuan, Taoyuan, Taiwan (Republic of China), ³National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁴Kaohsiung Veterans General Hospital, Kaohsiung, Kaohsiung, Taiwan (Republic of China), ⁵Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ⁶China Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), ⁷Tri-Service General Hospital, Taipei, Taipei, Taiwan (Republic of China), ⁸Fu Jen Catholic University Hospital, New Taipei, New Taipei, Taiwan (Republic of China), ⁹National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan (Republic of China), ¹¹Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹²¹. Tri-Service General Hospital, Taipei, Taiwan ². Kaohsiung Veteran General Hospital, Kaohsiung, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: Systemic glucocorticoid (GC) therapy is indispensable for treating active systemic lupus erythematosus (SLE) and lupus nephritis (LN), while contributing significantly to comorbidities and irreversible…
Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Ed Vital¹, George Bertsias², Andrea Doria³, Sindhu Johnson⁴, Sarah Mackie⁵, Sandra Navarra⁶, Bas Nijmeijer⁷, Ayobami Olojo⁷, Bernardo A. Pons-Estel⁸, Onno Teng⁹ and Jinoos Yazdany¹⁰, ¹University of Leeds, Leeds, England, United Kingdom, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³University of Padova, Padova, Italy, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Leeds, Leeds, United Kingdom, ⁶University of Santo Tomas, Manila, Philippines, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ⁹Leiden University Medical Center, Leiderdorp, Netherlands, ¹⁰UCSF, San Francisco, CA
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 2273 • ACR Convergence 2025
Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia
Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 0739 • ACR Convergence 2025
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Carmen Secada-Gómez¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Olga Maiz⁷, Rafael B. Melero-González⁸, Paloma Vela Casasempere⁹, Susana Romero-Yuste¹⁰, Jose Luis Callejas¹¹, Eugenio de Miguel¹², Eva Galíndez Agirregoikoa¹³, Francisca Sivera¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez Martín¹⁶ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donosti, Donostia, Spain, ⁸COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁴Hospital General Universitario Elda, Elda, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Hospital Universitario ¹² de Octubre, Madrid, Spain
Background/Purpose: Tocilizumab (TCZ) is the only approved biological drug in the treatment of giant cell arteritis (GCA). However, there are no comparative studies on the…
Abstract Number: 2117 • ACR Convergence 2025
Denosumab Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis: A Multi-site Randomized Clinical Trial
Giovanni Adami¹, Kenneth Saag², Gary Cutter³, Rahima Begum³, Elizabeth Dye⁴, Phillip Foster⁵, Camilla Benini⁶, Carmela Dartizio⁶, Davide Gatti⁶ and Maria I. ("Maio") Danila⁷, ¹University of Verona, Italy, Verona, Italy, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, ⁴UAB, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Verona, Verona, Italy, ⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Prompt anti-resorptive treatment with bisphosphonates after denosumab discontinuation is generally recommended. Glucocorticoid users may not require longer term denosumab and are at greater fracture…
Abstract Number: 1251 • ACR Convergence 2025
Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.
Michelle Petri¹, Martha Stone², John Stone³, meredith Marinaro⁴, Matt Wilkinson⁵, Walter Lentfert⁶, Camille Kotton⁷, Jeffrey Gelfand⁸, Jane McDowell⁹ and Tricha Shivas¹⁰, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Steritas, LLC, Concord, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Novartis, Hartford, CT, ⁵UpThereEverywhere, London, United Kingdom, ⁶UpThereEverywhere, Charlotte, NC, ⁷Harvard Medical School, Boston, MA, ⁸UCSF Department of Neurology, Mill Valley, CA, ⁹Queens University Belfast, Belfast, United Kingdom, ¹⁰Foundation for Sarcoidosis Research, Chicago, IL
Background/Purpose: We report on two years of engagement with Sam, a patient-facing program to optimize the use of glucocorticoids and discontinue them when possible. We…
Abstract Number: 0738 • ACR Convergence 2025
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Anisha Dua¹, Aditi Kadakia², Patrick Zueger³, Simran Marwaha⁴, Nathaniel Zerad³, Arathi Setty³, William Jones⁴ and Valerie Devauchelle⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AbbVie Inc, Woburn, MA, ³AbbVie Inc, North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵UBO, Brest, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in patients 50 years and older. Glucocorticoids (GC) are the mainstay of treatment for GCA…
Abstract Number: 1910 • ACR Convergence 2025
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Julie Mouchet¹, Tim Nguyen², Valeria Jordan M.³, G S Ramakrishna⁴, Linda Grinnell-Merrick², Andrew Heaney⁵, Anushka Mitra Das⁵, Pooja Shah⁶ and Evi Zhuleku⁷, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁴Novartis Healthcare Private Limited, Hyderabad, India, ⁵Novartis Ireland Ltd, Dublin, Ireland, ⁶Cytel Inc, Cambridge, ON, Canada, ⁷Cytel Inc, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions which predominantly affect individuals over the age of 50 years. The conditions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].